7380 COCA COLA DRIVE, HANOVER, MD
End of Material Contract
Processa Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price
1-for-25 Reverse Stock Split Approved for Processa Pharmaceuticals
Amended material disclosure
News
Shareholder votes
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Direct Registration System
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence